Tillkännagivande • Jun 20
LIR Life Sciences Corp. Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide LIR Life Sciences Corp. has completed its comparative mouse study evaluating protamine-enhanced skin permeation delivery of GLP/GIP-based therapies. The Study has now been completed for both semaglutide and tirzepatide, with closely aligned and reproducible results observed across the two molecules. Interim results from the Study demonstrated that a skin-applied protamine formulation of semaglutide could produce a meaningful reduction in blood glucose following an oral glucose challenge, approaching the glucose control profile observed with injectable administration. The final phase of the Study extended this same experimental framework to tirzepatide, a dual GLP-1/GIP receptor agonist, to assess whether similar skin permeability performance could be achieved with a second, structurally distinct incretin-based therapy. These results indicate that animals treated with a protamine-enabled topical formulation of tirzepatide exhibited glucose response profiles that were comparable to those observed with topical semaglutide, including blunting of post-challenge glucose excursions relative to untreated controls and sustained glucose stability over the observation period. The magnitude and shape of the glucose-lowering response following skin permeation administration were closely aligned between the two molecules, supporting the reproducibility of the platform across multiple GLP/GIP-based therapies. The Study also compared topical protamine formulations of semaglutide and tirzepatide against standard subcutaneous injection and untreated controls using a standardized glucose tolerance model. Completion of the Study for both compounds demonstrated that the observed skin permeation activity may not be limited to a single drug, but instead likely reflects a broader, molecule-agnostic capability of the protamine delivery system. With the comparative mouse Study now complete, LIR intends to use the full dataset to guide next steps in formulation optimization, dose refinement, and selection of lead candidates for subsequent preclinical and regulatory-enabling studies. The Company also notes that results from the Study were presented at ENDO 2026, the Endocrine Society’s annual meeting, held in Chicago, Illinois from June 13 to 16, 2026. The Company believes these results further support the potential of skin-applied, protamine-enabled delivery as a viable needle-free approach for incretin-based obesity therapies. New Risk • May 31
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.45m (US$8.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$8.69m). Board Change • May 20
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Kevin May is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • Jan 23
LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules LIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies. Tillkännagivande • Jan 16
LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity Therapies LIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science. 